- AMB302 recently received IND clearance from the U.S. Food and Drug
Administration (FDA).
- AimedBio plans to initiate a Phase 1 clinical trial in both Korea and the United States, enrolling patients with solid tumors, including bladder cancer and head and neck cancer.
- First patient dosing is expected to begin in Q1 2025 in both countries.